Logo

Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

Share this

Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

Shots:

  • Neurocrine Biosciences has reported the first patient dosing with NBI-1070770, for which the company gained rights for the development & commercialization from Takeda, under the P-II clinical evaluation
  • The multi-center, randomized, double-blind P-II (NBI-1070770-MDD2029) trial is to assess the efficacy, safety and tolerability of NBI-1070770 vs PBO to improve depression symptoms in major depressive disorder patients (n=72) across the US
  • NBI-1070770 (oral) is a novel and selective negative allosteric modulator (NAM) of the NR2B subunit-containing N-methyl-D-aspartate (NMDA NR2B) receptor designed to treat depressive disorder

Ref: Neurocrine | Image: Neurocrine

Related News:- GH Research’s Mebufotenin (5-MeO-DMT) and its Salt Products Receive European Patent for Major Depressive Disorder and Treatment-Resistant Depression

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions